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ABSTRACT 
Objective: To develop a simple and accurate RP-HPLC method for simultaneous estimation of organic impurities, enantiomer and assay of 
Dexlansoprazole, proposed method was validated according to an International Conference on Harmonisation of technical requirements for 
registration of pharmaceuticals for human use (ICH) guidelines.  
Methods: Cellulose tris-(3,5-dichlorophenylcarbamate) bonded on silica gel (Chiralpak IC) were used as stationary phase. Acetonitrile (ACN) and 10 
mM dibasic potassium phosphate buffer of pH 7.20, adjusted with dilute ortho phosphoric acid, were used as mobile phase in gradient composition 
at a flow rate of 1.0 ml/min. UV detection was made at 283 nm and run time was 27 min. 
Results: Limit of detection (LOD) and Limit of quantification (LOQ) was 42 and 126 ng/ml, respectively. Analytes response was studied from 0.25-1.50 
µg/ml and r2 value of the calibration curve was >0.999. Accuracy was studied in three different concentrations, the mean recovery was observed 
between 93.8 and 102.5%. To the maximum of 0.01% impurity variation was observed between the results of inter and intra-day precision. 
Conclusion: Proposed method is specific, precise, sensitive, linear and accurate. As a significance of this proposed method, the listed known 
impurities of Lansoprazole monograph [United States, British and European pharmacopoeias (USP/BP/Ph. Eur.)] Were used in method 
development and separation was demonstrated. Apart from this, enantiomer resolution was achieved and the same chromatogram was used for 
assay calculation. 
Keywords: Chiralpak IC, Cellulose tris-(3,5-dichlorophenylcarbamate), Dexlansoprazole, Method development, Simultaneous estimation, Lansoprazole. 
 
INTRODUCTION 
Chirality is an important one owing to the stereo dependent nature of 
biological actions [1]. Research has proved that drug enantiomers are 
different efficasy, even some drug enantiomers are adverse effect. 
Hence, enantiomer separation and quantification is the mandatory test 
along with organic impurities estimation in the field of pharmaceutical 
analysis. Enantiomers, related compounds estimation with two 
different methods was well established area in the field of liquid 
chromatography. In this aspect, combing these two tests and 
estimation of an assay in a single method was certainly useful for rapid 
drug analysis. In earlier studies to achieve this goal, combination of 
chemo (C-18) and enantio selective stationary phases (polysaccharide 
phenyl carbamate) were used in tandem with SFC technique [2], latter 
on same kind of study was reported on RP mode [3]. In practice 
bonded phase was used in achiral components separation, whereas 
phenyl derivative alkyl bonded stationary phases are recommended 
for special applications like positional isomer separation, because of 
additional π-π interaction. Polysaccharide phenyl carbamate 
derivatives are the best choice for enantiomer separation.  
However, there is a scope for chiral stationary phase (CSP) to be used 
in more efficient way [2]. Polysaccharide phenylcarbamate derivatives 
are widely used in enantiomer separation in coated form; these 
columns are limitations in solvent, hence utilisation of these columns 
to achieve the above goal (combing enantiomer, organic impurities 
and assay in one test) is challenge. RP mode with the gradient mobile 
phase composition was the preferred condition to achieve the goal, for 
these conditions immobilised CSP’s are suitable [4]. Dexlansoprazole is 
chemically known as R (+)-1H-Benzimidazole,2-[[[3-methoxyl-4-
(2,2,2-trifluoroethoxy)-2-pyridinyl] methyl] sulfinyl], is one of 
important proton pump inhibitor (PPI) that inhibits acid secretion in 
gastric parietal cells [5]. Numerous literatures were reported in 
Lansoprazole, for organic impurities estimation in drug substance, 
dosage form and biological substances [6-14]. Dexlansoprazole is the 
active drug compared with its enantiomer; this drug will be the 
therapeutic category of gastric acid secretion inhibitor. Varity of 
sulphoxide proton pump inhibitors are commercially available, in this 
aspect all relevant literatures are reviewed thoroughly for 
simultaneous estimation chemo and enantio selective method. Reports 
on enantioseparation, retention behaviour of proton pump inhibitors 
(PPI’s) on polysaccharide phenyl carbamate triad of stationary phases 
is quite abundant in the existing literature [15-24]. Immobilised 
polysaccharide phenyl carbamate derivative stationary phases are 
successful in solvent versatility and highest potential of chiral selective 
in RP-HPLC [4, 24]. Enantio and chemoselective HPLC method were 
reported for simultaneous estimation of enantiomer and organic 
impurities in Dexlansoprazole using Chiralpak IA column [19], but 
isocratic NP mode of separation. Consequently, one reported impurity 
was not eluted in proposed method (As per EP Lansoprazole Impurity-
D, i.e., 2-mercatobenzimidazole). 
However, the goal was not achieved. Proposed method was used as a 
chemoselective method for enantiomer estimation, hence method 
validation demonstrated with enantiomer and Dexlansoprazole. 
Continuation of the previous work Zanitti et al. proposed a method 
for direct enantio separation of omeprazole and its chiral impurities 
[20]. There is no other literature is available to describe about the 
simultaneous estimation of enantiomer, organic impurities and 
assay in Dexlansoprazole. Considering all the above literatures, and 
achieve the goal (combing enantiomer, organic impurities and assay 
in one test), this work was initiated. Lansoprazole USP listed 
impurities, enantiomer were used for method development and 
validation. Latter on additional two impurities which is listed in EP 
was purchased and resolution was demonstrated. Dexlansoprazole 
and related impurities structure is shown below. 
MATERIALS AND METHODS 
Materials  
HPLC grade acetonitrile, methanol, di potassium hydrogen 
orthophosphate anhydrous, ammonium acetate, phosphoric acid and 
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potassium hydroxide were obtained from Merck, Mumbai, India-400 
018. Dexlansoprazole, racemic Lansoprazole, related compounds-A, 
B, C and racemic N-oxide are prepared in Cipla Rand D, Bangalore, 
India-500 049.  
Related compound-D was purchased from Ph. Eur. Millipore Milli-Q 
plus water purifying system was used to purify the water (Millipore, 
USA). Cellulose tris-(3,5-dichlorophenylcarbamate) bonded on silica 
gel, Chiralpak IC column (250 mm x 4.6 mm, 5 µm) was procured 
from Daicel chiral technologies (India) Pvt. Ltd., Hyderabad, India-
500 078. 
HPLC and LCMS 
HPLC used for this study is Waters 2695 module series apparatus. It 
is equipped with the quaternary pump, degasser, auto injector and 
column oven compartment with 2996 module multi wave length 
PDA detector. Data was collected and processed using Empower 2 
chromatographic software. Agilent 1290 series UPLC equipped with 
binary gradient pump and detector was coupled with AB Sciex 5500 
series mass spectrometer was used for MS study. It is equipped with 
turbo spray ion source and Qtrap mass analyser, MS and MS/MS 
data were acquired and processed in Analyst software.  
 
 
Fig. 1: Chemical structure of Dexlansoprazole and its impurities 
 
Method scouting 
Immobilised phenyl carbamate polysaccharide derivative CSP’s are 
considered for combined approach, because of proven selectivity and 
solvent versatility [25]. Amylose tris-(3, 5-dimethyl phenyl 
carbamate), Cellulose tris-(3, 5-dichloro phenyl carbamate) stationary 
phases were used for method scouting; these columns are compatible 
in reverse phase mode. USP related compounds (N-oxide, Sulfone and 
Sulphide) along with related compound-C and enantiomer impurity 
was used in initial method development. Mobile phase gradient were 
applied to retain the polar and elute the non-polar compound in short 
analysis time.  
Methods (HPLC and LCMS) 
Preparation of phosphate buffer: 10 mM dibasic potassium 
phosphate buffer was prepared and pH of the solution was adjusted 
to 7.20 with dilute orthophosphoric acid. This buffer was used as 
mobile phase-A and ACN was used as a mobile phase-B at the flow 
rate of 1.0 ml/min in gradient composition. Gradient programme: 
Time (min)/A (v/v): B (v/v); T0.0/70:30;T20.0/ 30:70;T22.0/ 
70:30;T27.0/70:30). Chiralpak IC 250 mm, 4.6 mm, 5 µm column was 
used for separation. UV detection was at 283 nm and run time was 
27 min. Column oven temperature was maintained at 30 ºC. Sample 
concentration was 500 µg/ml and injection volume 10 µl. Instead of 
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phosphate buffer, 10 mM ammonium acetate pH 7.20 buffer was 
used for LCMS analysis other chromatographic conditions are 
remain same. 
Method validation 
Proposed method was validated as per ICHQ2 guidelines. Specificity, 
inter and intra-day precision, linearity, sensitivity and accuracy were 
performed.  
Specificity  
Gradient/diluent interference was checked at the retention time of 
analyte and its impurities, 1 µg/ml of individual impurities and 
Dexlansoprazole were injected in chromatographic system. 1 µg/ml 
of impurities are spiked in Dexlansoprazole and injected for system 
suitability. 
Repeatability and reproducibility 
Precision of the method was verified by repeatability and 
reproducibility studies. Six test solutions were prepared and 
injected in chromatographic system in a day and results are 
compared. Reproducibility was carried out, same as per 
repeatability study but different day in different instrument and 
results are compared.  
Sensitivity  
Series of dilute solutions was prepared and 10 µl injected in the 
chromatographic system. Sensitivity was reported as LOD and LOQ, 
signal to noise(S/n) ratio was the criterion set for sensitivity. S/n 
ratio ≥3 set for LOD, S/n ratio ≥ 10 with precision was set for LOQ. 
Triplicate was injected for LOD and six replicate injections were 
carried out for LOQ. Relative standard deviation of peak area 
response was calculated for LOQ replicates and 5% RSD set for limit.  
Calibration curve  
Analytes responses were studied in the range of 0.25-1.50 µg/ml (50 
to 300% of limit level concentration). Five point calibrations were 
carried out, in each level triplicate injections were made and average 
peak area responses are calculated and calibration curve was drawn 
against their respective concentrations. Linearity was evaluated by 
linear regression analysis, which was evaluated by least square 
regression method. Acceptance criteria set for linearity study were 
r2>0.999. 
Recovery  
Accuracy is one of the important parameter in method validation to 
evaluate the sample matrix effect on impurities response. Accuracy was 
carried out by recovery experiments. Related compounds-A, B, racemic 
Lansoprazole and N-oxide were spiked into the sample at 0.25, 0.50, 1.0 
µg/ml concentrations. Three preparations were prepared and injected in 
the chromatographic system. %Recovery was calculated and 90 to 110% 
of the recovery was the limit set for accuracy study. 
RESULTS AND DISCUSSION 
Column selection challenge 
Late 1980’s enantiomer separation is novel area, now very much 
familiar. Hence, last three decades variety of coated CSP’s was 
introduced in the market. Quite abundant literatures were available 
for enantio separation on coated CSP’s in NP mode. Separation of 
polar and non polar impurities in short run time on coated CSP in NP 
isocratic mode is challenge, such instance is, Cirilli et-al unable to 
elute one reported impurity, in his proposed method [19]. RP 
gradient mobile phase condition is the preferred choice for short 
and sensitive method, though immobilised CSP’s are chosen for 
combined method development, however very few immobilised 
chiral stationary phase columns are commercially available. 
MS study 
Racemic N-oxide was used in method development and validation 
study, though two peaks were eluting at the relative retention (RRT) of 
0.68 and 0.76 with respect to Dexlansoprazole. Configuration of these 
two N-oxide peaks was unknown, thus denoted as N-oxide 1 and 2. 
One impurity was observed in trace level at 0.57 RRT of 
Dexlansoprazole by MS and identified as m/z [(M+H)+] 402. Exact 
mass of this specified impurity was 401 Da (i.e., 32 Da more than 
Dexlansoprazole and 16 Da more than N-oxide), hence N-oxide and 
specified impurity was further fragmented in MS/MS to predict the 
probable structure. Common daughter ions (m/z 238, 204,119 and 
106) was observed in MS/MS though specified impurity is the related 
structure of N-oxide. 386, 268 mass was found in N-oxide fragments 
and corresponding 16 Da more mass 402 and 284 was observed in 
specified impurity. Hence specified impurity could be Suphone N-
oxide. MS, MS/MS spectrum of specified impurity and N-oxide were 
presented in fig. 2 for better understanding. From the evident of 




Fig. 2: MS spectrum of specified impurity and MS/MS spectrum of N-oxide and specified impurity 
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Fig. 3: Probable fragmentation pattern of N-oxide and specified impurity 
 
Specificity, Repeatability and reproducibility 
USP listed impurities are well separated with base line separation. 
Obtained peak purity values are evident for method specific. Related 
compound-D (i. e EP impurity-E) is not available during the method 
development, in order to make fully applicable for the developed 
method, this impurity was purchased from European directorate for 
the quality of medicines and healthcare (EDQM) and specificity was 
demonstrated along with the adjacent peak of related compound-C. 
Typical system suitability chromatogram was shown in fig. 4. The 
chromatogram of dexlansoprazole related compounds C and D is 
shown in fig. 5 and specificity values are presented in below for 
better understanding. 
  
Table 1: Specificity results 
Name of the analyte Retention time Capacity factor (k) Resolution (Rs) Tailing factor (T) 
Related compound-D 3.97 0.32 - 0.93 
Related compound-C 4.44 0.48 - 1.10 
N-oxide 1 8.80 2.62 15.23 1.04 
Related compound-A 9.41 2.86 1.95 1.01 
N-oxide 2 9.94 3.08 1.64 1.06 
Enantiomer 11.76 3.84 5.49 1.09 
Dexlansoprazole 13.02 4.37 3.94 1.03 
Related compound-B 16.79 5.91 11.43 1.04 
500 µg/ml of Dexlansoprazole spiked with 1 µg/ml of impurities and injected for specificity and system suitability purpose 
 
 
Fig. 4: Typical system suitability chromatogram of dexlansoprazole spiked with impurities 
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Fig. 5: Zoomed chromatogram of dexlansoprazole related compounds C and D (EP impurities D and E) 
 
Results obtained in repeatability and reproducibility results are 
comparable and maximum 0.01% of impurity variation observed 
between the replicates. Hence the proposed method is repeatable 
and reproducible.  
Sensitivity (LOQ and LOD) 
Racemic N-oxide, related compound-A, B, and racemic Lansoprazole 
were diluted and injected in the chromatographic system. S/n 
ratio>3 were observed for 0.008% of analytes concentration with 
respect to sample, hence this concentration was considered as LOD. 
S/n ratio>10 were observed for 0.025% of analytes concentration 
with<4% RSD of peak area responses of LOQ replicates. 
Quantification limit of impurities in the proposed method is 0.025%, 
thus<0.025% of impurities can be disregarded in purity test. 
Sensitivity results are presented in table 2.  
In method sensitivity aspect, minimum 50% of the limit level 
concentration to be achieved as a LOQ. Proposed method LOQ has 
been observed apparently 17% of limit level concentrations with 
good precision. 500 µg/ml sample concentration were used for 
impurity and assay estimation as well. Considering this test 
concentration LOD, LOQ was established. Above results clearly insist 
that developed method is good sensitive. 
  
Table 2: Sensitivity data 









%RSD RT (n=6) %RSD Area(n=6) 
N-Oxide 1 42 3 126 14 0.1 3.6 
Related compound-A 42 5 126 17 0.1 3.9 
N-Oxide 2 42 3 126 13 0.1 1.4 
Enantiomer 42 6 126 14 0.1 2.5 
Dexlansoprazole 42 6 126 13 0.1 1.4 
Related compound-B 42 5 125 15 0.1 1.5 
n=6, six determinations. 0.025% and 0.008% is the LOQ and LOD concentrations with respect to test concentration (500 µl/ml test concentration 
was used for assay and impurities estimation) 
 
Table 3: Linearity data 













N-Oxide 1 0.2501 0.5002 0.7503 1.0004 1.5005 0.9999 2535x-16 
Related compound-A 0.2529 0.5058 0.7586 1.0115 1.5173 0.9999 1994x-17 
N-Oxide 2 0.2501 0.5002 0.7503 1.0004 1.5005 0.9999 2524x-44 
Enantiomer 0.2510 0.5020 0.7530 1.0040 1.5060 0.9999 2227x-37 
Dexlansoprazole 0.2510 0.5020 0.7530 1.0040 1.5060 0.9993 2231x-43 
Related compound-B 0.2498 0.4997 0.7495 0.9993 1.4990 0.9999 2301x-55 
0.05, 0.10, 0.15, 0.20and0.30% with respect to sample concentrations were injected in triplicate for linearity study 
 
Table 4: Average % recovery 
Spiked conc. N-Oxide-1 Related compound-A N-Oxide-1 Enantiomer Related compound-B 
50% 98.79 96.12 102.11 98.40 99.20 
100% 95.22 93.78 102.52 96.36 101.99 
200% 97.82 97.42 102.29 98.79 99.82 
0.05, 0.10and0.20% with respect to sample concentrations of known impurities were spiked and injected in triplicate for accuracy study and 
average values are reported 
 
Calibration curve 
Linear response was observed over the range of 50-300% against 
the respective concentrations. Analytes calibration curve was 
evaluated thoroughly, regression coefficient r2 was observed>0.999. 
Concentration details, r2, and linearity equation were presented in 
table 3. 
Recovery 
Results obtained in accuracy study were well within the limit set for 
acceptance criteria. There is no impact on the results with sample 
matrix. Lowest average recovery was 93.8% and highest was 
102.5%. Accuracy data were presented in table 4. Hence, proposed 
method was accurate. 
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Proposed method is chemo and enantio specific with short run time 
(27 min), and the same method is applicable to assay estimation. 
Interestingly, immobilised phenyl carbamate chiral stationary phase 
was used in this study in efficient way, and as a benefit of this, the 
analysis time of Dexlansoprazole drug was reduced. Overall, the 
proposed and validated short and simple method of the immobilised 
polysaccharide phenylcarbamate derivative with gradient reverse 
phase mode is the best approach for a successful “combined method 
development”.  
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